NASDAQ:VCELVericel Stock Price, Forecast & News

Vericel's stock was trading at $12.08 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, VCEL stock has increased by 25.1% and is now trading at $15.11. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Vericel.

Vericel is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Vericel.

Vericel Corp (NASDAQ:VCEL) posted its quarterly earnings results on Tuesday, May, 5th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.02. The biotechnology company earned $26.70 million during the quarter, compared to the consensus estimate of $26.23 million. Vericel had a negative net margin of 9.39% and a positive return on equity of 5.87%. The firm's revenue was up 22.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.07) earnings per share. View Vericel's earnings history.

5 brokerages have issued 12-month price objectives for Vericel's shares. Their forecasts range from $21.00 to $32.00. On average, they anticipate Vericel's stock price to reach $24.25 in the next year. This suggests a possible upside of 60.5% from the stock's current price. View analysts' price targets for Vericel.

Headlines about VCEL stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Vericel earned a daily sentiment score of 0.7 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Vericel.

Some companies that are related to Vericel include Denali Therapeutics (DNLI), Bill.com (RVMD), Twist Bioscience (TWST), Alector (ALEC), SpringWorks Therapeutics (SWTX), Adverum Biotechnologies (ADVM), Editas Medicine (EDIT), I-Mab (BDTX), Beam Therapeutics (BEAM), Sorrento Therapeutics (SRNE), Regenxbio (RGNX), Mesoblast (MESO), Sangamo Therapeutics (SGMO), Cortexyme (CRTX) and NanoString Technologies (NSTG). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Momo (MOMO), Novavax (NVAX), Amarin (AMRN), Synergy Pharmaceuticals (SGYP), Dynavax Technologies (DVAX), NVIDIA (NVDA), Verastem (VSTM), Sorrento Therapeutics (SRNE) and TG Therapeutics (TGTX).

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VCEL stock can currently be purchased for approximately $15.11.

Vericel has a market capitalization of $681.63 million and generates $117.85 million in revenue each year. The biotechnology company earns $-9,660,000.00 in net income (profit) each year or $0.18 on an earnings per share basis. Vericel employs 216 workers across the globe.

The official website for Vericel is www.vcel.com.

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-588-5555 or via email at [email protected]